NDAORALTABLET
Approved
Jan 2012
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Mechanism of Action
Dipeptidyl Peptidase 4 Inhibitors
Pharmacologic Class:
Dipeptidyl Peptidase 4 Inhibitor
Clinical Trials (1)
Two-way Crossover Study in Healthy Male and Female Subjects to Evaluate the Bioequivalence of Jentadueto®.
Started Nov 2013
36 enrolled
Healthy
Loss of Exclusivity
LOE Date
Dec 8, 2037
143 months away
Patent Expiry
Dec 8, 2037
Exclusivity Expiry
Dec 20, 2026
Patent Records (5)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8883805 | Nov 26, 2025Expired | Product | — |
| 8883805*PED | May 26, 2026 | — | |
| 8673927 | May 4, 2027 | U-1503 | |
| 8673927*PED | Nov 4, 2027 | — | |
| 10022379 | Apr 2, 2029 | U-2339 |